Skip to main content
Top
Published in: Rheumatology International 4/2010

01-02-2010 | Original Article

Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved

Authors: Ralf G. Thiele, Naomi Schlesinger

Published in: Rheumatology International | Issue 4/2010

Login to get access

Abstract

This study aimed at determining whether lowering serum urate (SU) to less than 6 mg/dl in patients with gout affects ultrasonographic findings. Seven joints in five patients with monosodium urate (MSU) crystal proven gout and hyperuricemia were examined over time with serial ultrasonography. Four of the five patients were treated with urate lowering drugs (ULDs) (allopurinol, n = 3; probenecid, n = 1). One patient was treated with colchicine alone. Attention was given to changes in a hyperechoic, irregular coating of the hyaline cartilage in the examined joints (double contour sign or “urate icing”). This coating was considered to represent precipitate of MSU crystals. Index joints included metacarpophalangeal (MCP) joints (n = 2), knee joints (n = 3), and first metatarsophalangeal (MTP) joints (n = 2). The interval between baseline and follow-up images ranged from 7 to 18 months. Serial SU levels were obtained during the follow-up period. During the follow-up period, three patients treated with ULD (allopurinol, n = 2; probenecid, n = 1) achieved a SU level of <6 mg/dl. In two patients, SU levels remained above 6 mg/dl (treated with allopurinol, n = 1; treated with colchicine, n = 1). At baseline, the double contour sign was seen in all patients. In those patients who achieved SU levels of <6 ml/dl, this sign had disappeared at follow-up. Disappearance of the double contour sign was seen in two knee joints, two first MTP joints, and one MCP joint. In contrast, disappearance of the double contour sign was not seen in patients who maintained a SU level ≥7 mg/dl. In one patient treated with allopurinol, SU levels improved from 13 to 7 mg/dl during the follow-up period. Decrease, but not resolution of the hyperechoic coating was seen in this patient. In the patient treated with colchicine alone, SU levels remained >8 mg/dl, and no sonographic change was observed. In our patients, sonographic signs of deposition of MSU crystals on the surface of hyaline cartilage disappeared completely if sustained normouricemia was achieved. This is the first report showing that characteristic sonographic changes are influenced by ULDs once SU levels remain ≤6 mg/dl for 7 months or more. Sonographic changes of gout correlate with SU levels and may be a non-invasive means to track changes in the uric acid pool. Larger prospective studies are needed to further assess these potentially important findings.
Literature
1.
go back to reference Schlesinger N (2005) Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 11:S443–S450 quiz S65–S68PubMed Schlesinger N (2005) Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 11:S443–S450 quiz S65–S68PubMed
2.
go back to reference Garrod AB (1859) The nature and treatment of gout and rheumatic gout. Walton and Maberly, London Garrod AB (1859) The nature and treatment of gout and rheumatic gout. Walton and Maberly, London
3.
9.
go back to reference Bole GGJ (1985) Rheumatic diseases. In: Sodeman WAJ, Sodeman TM (eds) Pathologic physiology: mechanisms of disease. WB Saunders, Philadelphia, pp 485–513 Bole GGJ (1985) Rheumatic diseases. In: Sodeman WAJ, Sodeman TM (eds) Pathologic physiology: mechanisms of disease. WB Saunders, Philadelphia, pp 485–513
10.
go back to reference Felig P, Havel RJ, Smith LH Jr (1985) Metabolism. In: Smith LH Jr, Thier SO (eds) Pathophysiology: the biological principles of disease. WB Saunders, Philadelphia, pp 321–439 Felig P, Havel RJ, Smith LH Jr (1985) Metabolism. In: Smith LH Jr, Thier SO (eds) Pathophysiology: the biological principles of disease. WB Saunders, Philadelphia, pp 321–439
11.
go back to reference Schumacher HR Jr (1988) Pathology of crystal deposition diseases. Rheum Dis Clin North Am 14:269–288PubMed Schumacher HR Jr (1988) Pathology of crystal deposition diseases. Rheum Dis Clin North Am 14:269–288PubMed
12.
go back to reference Remagen W (1989) Skeletal system. In: Grundmann E, Geller SA (eds) Histopathology: color atlas of organs and systems. Urban & Schwarzenberg, Munich, pp 189–202 Remagen W (1989) Skeletal system. In: Grundmann E, Geller SA (eds) Histopathology: color atlas of organs and systems. Urban & Schwarzenberg, Munich, pp 189–202
13.
go back to reference Department of Pathology, University of Alabama at Birmingham (2006) Gout: gross natural color close-up of extensive uric acid deposits. PEIR digital library Image# 4034. Department of Pathology, University of Alabama at Birmingham, Birmingham Department of Pathology, University of Alabama at Birmingham (2006) Gout: gross natural color close-up of extensive uric acid deposits. PEIR digital library Image# 4034. Department of Pathology, University of Alabama at Birmingham, Birmingham
17.
go back to reference Thiele RG, Anandarajah AP, Tabechian D, Schlesinger N (2008) Comparing ultrasonography, MRI, conventional radiography, high-resolution CT and 3D rendering in patients with crystal proven gout. Ann Rheum Dis 67(Suppl II):248. doi:10.1136/ard.2007.072819 Thiele RG, Anandarajah AP, Tabechian D, Schlesinger N (2008) Comparing ultrasonography, MRI, conventional radiography, high-resolution CT and 3D rendering in patients with crystal proven gout. Ann Rheum Dis 67(Suppl II):248. doi:10.​1136/​ard.​2007.​072819
18.
21.
go back to reference Yu KH (2003) Intraarticular tophi in a joint without a previous gouty attack. J Rheumatol 30:1868–1870PubMed Yu KH (2003) Intraarticular tophi in a joint without a previous gouty attack. J Rheumatol 30:1868–1870PubMed
24.
go back to reference Bjelle AO (1972) Morphological study of articular cartilage in pyrophosphate arthropathy (chondrocalcinosis articularis or calcium pyrophosphate dihydrate crystal deposition diseases). Ann Rheum Dis 31:449–456. doi:10.1136/ard.31.6.449 CrossRefPubMed Bjelle AO (1972) Morphological study of articular cartilage in pyrophosphate arthropathy (chondrocalcinosis articularis or calcium pyrophosphate dihydrate crystal deposition diseases). Ann Rheum Dis 31:449–456. doi:10.​1136/​ard.​31.​6.​449 CrossRefPubMed
26.
go back to reference Filippucci E, Gutierrez Riveros M, Georgescu D, Salaffi F, Grassi W (2009) Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthritis Cartilage 17(2):178–181CrossRefPubMed Filippucci E, Gutierrez Riveros M, Georgescu D, Salaffi F, Grassi W (2009) Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthritis Cartilage 17(2):178–181CrossRefPubMed
28.
Metadata
Title
Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved
Authors
Ralf G. Thiele
Naomi Schlesinger
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1002-8

Other articles of this Issue 4/2010

Rheumatology International 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.